Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,222,000 | 1,467,000 | 672,000 | 1,846,000 | 1,284,000 |
| Depreciation Amortization | 1,049,000 | 707,000 | 325,000 | 1,655,000 | 1,197,000 |
| Income taxes - deferred | 20,000 | -49,000 | 41,000 | -70,000 | 10,000 |
| Accounts receivable | -171,000 | -139,000 | -107,000 | -351,000 | -261,000 |
| Other Working Capital | -401,000 | -445,000 | -685,000 | -462,000 | -786,000 |
| Other Operating Activity | 451,000 | 286,000 | 295,000 | 817,000 | 535,000 |
| Operating Cash Flow | $3,170,000 | $1,827,000 | $541,000 | $3,435,000 | $1,979,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -525,000 | -344,000 | -187,000 | -787,000 | -513,000 |
| Net Acquisitions | -1,504,000 | -1,248,000 | -239,000 | -4,640,000 | -1,222,000 |
| Purchase Of Investment | N/A | -110,000 | -77,000 | -280,000 | N/A |
| Other Investing Activity | -99,000 | 76,000 | 3,000 | 20,000 | -248,000 |
| Investing Cash Flow | $-2,128,000 | $-1,626,000 | $-500,000 | $-5,687,000 | $-1,983,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 211,000 | N/A |
| Debt Issued | 1,558,000 | 1,558,000 | 1,558,000 | 2,145,000 | 2,145,000 |
| Debt Repayment | -49,000 | -42,000 | -36,000 | -25,000 | -25,000 |
| Common Stock Issued | 262,000 | 147,000 | 115,000 | 230,000 | 202,000 |
| Other Financing Activity | -1,982,000 | -1,770,000 | -1,404,000 | -747,000 | -722,000 |
| Financing Cash Flow | $-211,000 | $-107,000 | $233,000 | $1,814,000 | $1,600,000 |
| Exchange Rate Effect | 39,000 | 41,000 | 39,000 | -11,000 | -2,000 |
| Beginning Cash Position | 606,000 | 606,000 | 606,000 | 1,055,000 | 1,055,000 |
| End Cash Position | 1,476,000 | 741,000 | 919,000 | 606,000 | 2,649,000 |
| Net Cash Flow | $870,000 | $135,000 | $314,000 | $-450,000 | $1,594,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,170,000 | 1,827,000 | 541,000 | 3,435,000 | 1,979,000 |
| Capital Expenditure | -525,000 | -344,000 | -187,000 | -790,000 | -513,000 |
| Free Cash Flow | 2,645,000 | 1,483,000 | 354,000 | 2,645,000 | 1,466,000 |